Quoin Pharmaceuticals CEO Michael Myers buys $99,991 ADSs

Quoin Pharmaceuticals' CEO, Michael Myers, recently expanded his stake in the company by purchasing 20,490 American Depositary Shares (ADSs) for a total of $99,991. Purchased at a rate of $4.88 per ADS on August 31, 2026, the investment has since appreciated to a value of $6.51 per ADS, marking a 26% increase from the initial purchase price.

This move was part of a private placement transaction, and following the purchase, Myers now directly owns a total of 37,713 ADSs. Each ADS represents 35 ordinary shares of Quoin Pharmaceuticals, Ltd. An analysis of the stock, conducted by InvestingPro, indicates that it may be overvalued at this time, with 11 ProTips available for subscribers interested in deeper analysis of the company's financial situation and future prospects.

In a related transaction, Myers also acquired 10,245 ordinary warrants as part of the same private placement. Each warrant, acquired at the same price of $4.88, has an exercise price of $6.10 and provides the holder with the right to purchase up to 10,245 ADSs. These warrants became exercisable immediately upon issuance, subject to certain limitations on beneficial ownership, and will expire five years from the issuance date or within 30 days of the company announcing the successful completion of its clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome, whichever comes first.

Quoin Pharmaceuticals has also announced plans to establish a wholly-owned subsidiary in Japan to facilitate the potential commercialization of QRX003, a drug being developed for the treatment of Netherton Syndrome. The company received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare, which is expected to streamline interactions with Japanese regulators, healthcare professionals, and patient advocacy groups.

Additionally, Quoin Pharmaceuticals submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for QRX003's potential use in treating Peeling Skin Syndrome, a rare skin disorder with currently no approved treatments. The company intends to initiate a Phase 2 clinical trial for QRX003 in the second half of 2026, pending FDA approval.

These recent actions underscore Quoin Pharmaceuticals' strategic focus on advancing its pipeline of therapies for rare diseases.